Free radical attenuation prevents thrombosis and enables photochemical inhibition of vein graft intimal hyperplasia

Journal of Vascular Surgery

Volumn 39, Issue 4, 2004, Pages 843-849

  Nigri, Giuseppe R ^a,b   Kossodo, Sylvie ^a,b   Waterman, Peter ^a,b   Fungaloi, Patrick ^a,b   LaMuraglia, Glenn M ^a,b,c  

^a Harvard Medical School ^*

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c HARVARD UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DEFEROXAMINE; FREE RADICAL; GRANULOCYTE ANTIBODY; HYDROXYL RADICAL; IRON LOADED DEFEROXAMINE; PHOTOSENSITIZING AGENT; TETRASULFOPHTHALOCYANINE CHLOROALUMINUM; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTERY INTIMA PROLIFERATION; ARTICLE; CELL ADHESION; COMMON CAROTID ARTERY; CONTROLLED STUDY; DRUG MECHANISM; FENTON REACTION; JUGULAR VEIN; NEUTROPHIL CHEMOTAXIS; NONHUMAN; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; RAT; REPERFUSION INJURY; THROMBOSIS; VEIN BYPASS; VEIN GRAFT;

EID: 1642464778     PISSN: 07415214     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jvs.2003.11.028     Document Type: Article

References (35)

1. Motwani JG, Topol EJ. Aortocoronary saphenous vein graft disease: pathogenesis, predisposition, and prevention. Circulation 1998;97: 916-31.
2. Dobrin PB, Littooy FN, Endean ED. Mechanical factors predisposing to intimal hyperplasia and medial thickening in autogenous vein grafts. Surgery 1989;105:393-400.
3. Ortu P, LaMuraglia GM, Roberts WG, Flotte TJ, Hasan T. Photodynamic therapy of arteries: a novel approach for treatment of experimental intimal hyperplasia. Circulation 1992;85:1189-96.
4. Jenkins MP, Buonaccorsi GA, Mansfield R, Bishop CC, Bown SG, McEwan JR. Reduction in the response to coronary and iliac artery injury with photodynamic therapy using 5-aminolaevulinic acid. Cardiovasc Res 2000;45:478-85.
5. Jenkins MP, Buonaccorsi GA, Raphael M, Nyamekye I, McEwan JR, Bown SG, et al. Clinical study of adjuvant photodynamic therapy to reduce restenosis following femoral angioplasty. Br J Surg 1999;86: 1258-63.
6. Woodburn KW, Fan Q, Kessel D, Wright M, Mody TD, Hemmi G, et al. Phototherapy of cancer and atheromatous plaque with texaphyrins. J Clin Laser Med Surg 1996;14:343-8.
7. Rockson SG, Lorenz DP, Cheong WF, Woodburn KW. Photoangioplasty: an emerging clinical cardiovascular role for photodynamic therapy. Circulation 2000;102:591-6.
8. Rockson SG, Kramer P, Razavi M, Szuba A, Filardo S, Fitzgerald P, et al. Photoangioplasty for human peripheral atherosclerosis: results of a phase I trial of photodynamic therapy with motexafin lutetium (Antrin). Circulation 2000;102:2322-4.
9. Hansen PR. Role of neutrophils in myocardial ischemia and reperfusion. Circulation 1995;91:1872-85.
10. Weiss SJ. Tissue destruction by neutrophils. N Engl J Med 1989;320: 365-76.
11. Badwey JA, Karnovsky ML. Active oxygen species and the functions of phagocytic leukocytes. Annu Rev Biochem 1980;49:695-726.
12. Kloner RA, Przyklenk K, Whittaker P. Deleterious effects of oxygen radicals in ischemia/reperfusion: resolved and unresolved issues. Circulation 1989;80:1115-27.
13. Reddy BR, Kloner RA, Przyklenk K. Early treatment with deferoxamine limits myocardial ischemic/reperfusion injury. Free Radical Biol Med 1989;7:45-52.
14. Stahl GL, Halliwell B, Longhurst JC. Hydrogen peroxide-induced cardiovascular reflexes: role of hydroxyl radicals. Circ Res 1992;71:295-302.
15. Dougherty TJ. An update on photodynamic therapy applications. J Clin Laser Med Surg 2002;20:3-7.
16. Dougherty TJ, Gomer CJ, Henderson BW, Jori G, Kessel D, Korbelik M, et al. Photodynamic therapy. J Natl Cancer Inst 1998;90:889-905.
17. Statius van Eps RG, Mark LL, Schiereck J, LaMuraglia GM. Photodynamic therapy inhibits the injury-induced fibrotic response of vascular smooth muscle cells. Eur J Vasc Endovasc Surg 1999;18:417-23.
18. LaMuraglia GM, ChandraSekar NK, Flotte TJ, Abbott WM, Michaud N, Hasan T. Photodynamic therapy inhibition of experimental intimal hyperplasia: acute and chronic effects. J Vasc Surg 1994;19:321-9 discussion 329-31.
19. Woodburn KW. Ateromatous plaque reduction with Antrin photoangioplasty. Laser Surg Med 1999;11(suppl):53.
20. LaMuraglia GM, Klyachkin ML, Adili F, Abbott WM. Photodynamic therapy of vein grafts: suppression of intimal hyperplasia of the vein graft but not the anastomosis. J Vasc Surg 1995;21:882-90; discussion 889-90.
21. Yamaguchi A, Woodburn KW, Hayase M, Robbins RC. Reduction of vein graft disease using photodynamic therapy with motexafin lutetium in a rodent isograft model. Circulation 2000;102:III275-80.
22. Yamaguchi A, Woodburn KW, Hayase M, Hoyt G, Robbins RC. Photodynamic therapy with motexafin lutetium (Lu-Tex) reduces experimental graft coronary artery disease. Transplantation 2001;71: 1526-32.
23. LaMuraglia GM, Adili F, Schmitz-Rixen T, Michaud NA, Flotte TJ. Photodynamic therapy inhibits experimental allograft rejection: a novel approach for the development of vascular bioprostheses. Circulation 1995;92:1919-26.
24. Huynh TT, Davies MG, Trovato MJ, Barber L, Safi HJ, Hagen PO. Reduction of lipid peroxidation with intraoperative superoxide dismutase treatment decreases intimal hyperplasia in experimental vein grafts. J Surg Res 1999;84:223-32.
25. 2 and hydroxyl radicals. Am J Physiol 1995;269:H888-901.
26. Han SL, Abe Y, Miyauchi K, Watanabe Y, Sato N, Kimura S. Therapeutic efficacy of an antineutrophil monoclonal antibody, Urge-8, against acute necrotizing pancreatitis in rats. Surgery 1996;119:585-91.
27. Chen YX, Sato M, Abe Y, Kito K, Watanabe Y, Tokui K, et al. Protective effect of an antineutrophil antibody, Urge-8, on liver ischemia-reperfusion injury in a new hepatic ischemia model. Transplant Proc 2000;32: 2318-9.
28. Gates JD, Hirsch GM, Karnovsky MJ. Suppressors of oxygen metabolites fail to reduce vein graft intimal hyperplasia. Arch Surg 1995;130: 976-80.
29. Davis MG, Dalen H, Austerheim AM, Gulbrandsen TF, Svendsen E, Hagen PO. Suppression of intimal hyperplasia in experimental vein grafts by oral 1-arginine supplementation and single ex vivo immersion in deferoxamine manganese. J Vasc Surg 1996;23:410-20.
30. Hagen PO, Davies MG, Schuman RW, Murray JJ. Reduction of vein graft intimal hyperplasia by ex vivo treatment with desferoxamine manganese. J Vasc Res 1992;29:405-9.
31. LaMuraglia GM, Schiereck J, Heckenkamp J, Nigri G, Waterman P, Leszczynski D, et al. Photodynamic therapy induces apoptosis in intimal hyperplastic arteries. Am J Pathol 2000;157:867-75.
32. Waterman PR, Overhaus M, Heckenkamp J, Nigri GR, Fungaloi PF, Landis ME, et al. Mechanisms of reduced human vascular cell migration after photodynamic therapy. Photochem Photobiol 2002;75:46-50.
33. Statius van Eps RG, Adili F, LaMuraglia GM. Photodynamic therapy inactivates cell-associated basic fibroblast growth factor: a silent way of vascular smooth muscle cell eradication. Cardiovasc Res 1997;35: 334-40.
34. Statius van Eps RG, LaMuraglia GM. Photodynamic therapy inhibits transforming growth factor beta activity associated with vascular smooth muscle cell injury. J Vasc Surg 1997;25:1044-52; discussion 1052-3.
35. Statius van Eps RG, Adili F, Watkins MT, Anderson RR, LaMuraglia GM. Photodynamic therapy of extracellular matrix stimulates endothelial cell growth by inactivation of matrix-associated transforming growth factor-beta. Lab Invest 1997;76:257-66.